June 4, 2019 / 3:18 PM / 3 months ago

BRIEF-Roche Holding Announces Phase III CLL14 Results For Venclexta/Venclyxto With Gazyva/Gazyvaro

June 4 (Reuters) - ROCHE HOLDING AG:

* PIVOTAL PHASE III CLL14 RESULTS FOR VENCLEXTA/VENCLYXTO IN COMBINATION WITH GAZYVA/GAZYVARO FOR CHRONIC LYMPHOCYTIC LEUKAEMIA PRESENTED AT ASCO 2019 AND PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

* VENCLEXTA/VENCLYXTO PLUS GAZYVA/GAZYVARO SHOWED IMPROVEMENTS ACROSS MULTIPLE MEASURES COMPARED TO GAZYVA/GAZYVARO PLUS CHLORAMBUCIL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below